NIKA PHARMACEUTICALS, INC (NIKA): M&A transaction — Nika Pharma acquires 40% of Nika Europe, now owns 80%; buys 4 technologies for $24,683

NIKA PHARMACEUTICALS, INC

Merger with Nika BioTechnology gave Nika Pharma an additional 40% stake in Nika Europe Ltd, bringing total to 80%.
Nika Europe Ltd acquired three generic drug technologies and one dietary supplement technology from AIPFPCB.
Purchase price was 45,000 BGN (~$24,683), paid by officer Dimitar Savov, who is also general manager of Nika Europe.
Acquired drug technologies: Menthyl Valerate 0.06g, Metamizole Sodium 500mg, Vinpocetine 10mg; supplement: Tribulus Terrestris extract 250mg.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NIKA PHARMACEUTICALS, INC completed an acquisition involving Nika BioTechnology, Inc. (closed 2024-04-10).

Action: acquisition
Counterparty: Nika BioTechnology, Inc.
Closing: 2024-04-10

Exact text from the filing

Pursuant to the terms of the merger of Nika BioTechnology, Inc. into Nika Pharmaceuticals, Inc., Nika Pharmaceuticals, Inc. has acquired the 40% stake in Nika Europe Ltd. that was owned by Nika BioTechnonoly, Inc.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NIKA PHARMACEUTICALS, INC completed an acquisition involving Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology for 45,000 BGN (equivalent to around 24,683 USD).

Action: acquisition
Counterparty: Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology
Consideration: 45,000 BGN (equivalent to around 24,683 USD)

Exact text from the filing

a dietary supplement. The technologies were purchased from Alliance for Intellectual Property in the Field of Pharmacy, Chemistry, and Biology (“AIPFPCB”) for a total price of 45,000 BGN (equivalent to around 24,683 USD) that was paid by Dimitar Slavchev Savov who is an officer and director of Nika Pharmaceuticals, Inc. and the general manager of Nika

View on SEC.gov

Browse all m&a transactions →

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.